Healthcare / BiotechnologyKOSDAQ
$5550.00
+50.00 (+0.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-20.5B · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$199.4B
P/E
N/A
•EV/EBITDA
65.1x
↑ROE
-6.1%
↓Gross Margin
54.5%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.4%
FCF CAGR
—
FCF margin
-76.8%
FCF / Net income
2.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $24.59B · net income $-6.43B · FCF $-18.88B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $24.59B | $24.59B | $27.74B | $14.30B | $14.08B |
| Net Income | $-6.43B | $-6.43B | $-20.11B | $-47.47B | $-51.84B |
| EBITDA | $2.72B | $2.72B | $-17.23B | $-41.84B | $-48.40B |
| EPS | -205.00 | -205.00 | -660.00 | -840.00 | -1841.50 |
| Gross Margin | 54.5% | 54.5% | 56.5% | 28.4% | 39.7% |
| Operating Margin | -118.9% | -118.9% | -87.2% | -385.4% | -408.3% |
| Net Margin | -26.1% | -26.1% | -72.5% | -332.0% | -368.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.66 | 0.42 | 0.06 |
| Current Ratio | 1.49 | 1.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.88B | $-18.88B | $-20.52B | $-51.27B | $-50.83B |
| Returns | |||||
| ROE | -6.1% | -6.1% | -41.6% | -76.0% | -53.3% |
| Valuation | |||||
| EV/EBITDA | 65.12 | 65.12 | — | — | — |
| P/B | 1.65 | 1.65 | 1.86 | 5.52 | 5.08 |
| Growth & Yield | |||||
| Revenue Growth | -11.4% | -11.4% | 94.1% | 1.5% | — |
| EPS Growth | 68.9% | 68.9% | 21.4% | 54.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+111.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-660.00 → -205.00
Residual
+111.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.